CLINDESSE (clindamycin phosphate)
VAGINAL ANTI-INFECTIVES · BACTERIAL VAGINOSIS
Padagis US
Drug class
Clindamycin Vaginal
Rather than a distinct pharmacological class, "clindamycin vaginal" refers to route- and site-specific formulations—such as creams, gels, and ovules or suppositories—of clindamycin, a semisynthetic lincosamide antibacterial agent. Read more about Clindamycin Vaginal
11 drugs in this class 6 manufacturers
Drugs in Clindamycin Vaginal
CLINDAMYCIN PHOSPHATE
ACNE ANTIBIOTICS · ACNE VULGARIS
GREENSTONE-MYLA
Filter & compare in the drug finder →
Opens the drug finder with Clindamycin Vaginal preselected. Add indication or manufacturer filters there.
Rather than a distinct pharmacological class, "clindamycin vaginal" refers to route- and site-specific formulations—such as creams, gels, and ovules or suppositories—of clindamycin, a semisynthetic lincosamide antibacterial agent.
It exerts its therapeutic effect locally by binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting bacterial protein synthesis with minimal systemic absorption.
In clinical practice, these topical formulations are primarily indicated for the treatment of bacterial vaginosis in non-pregnant and pregnant patients.
-
fda.gov
Rather than a distinct pharmacological class, "clindamycin vaginal" refers to route- and site-specific formulations—such as creams, gels, and ovules or suppositories—of clindamycin, a semisynthetic lincosamide antibacterial agent It exerts its therapeutic effect locally by binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting bacterial protein synthesis with minimal systemic absorption In clinical practice, these topical formulations are primarily indicated for t...
-
mayoclinic.org
Rather than a distinct pharmacological class, "clindamycin vaginal" refers to route- and site-specific formulations—such as creams, gels, and ovules or suppositories—of clindamycin, a semisynthetic lincosamide antibacterial agent
-
goodrx.com
It exerts its therapeutic effect locally by binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting bacterial protein synthesis with minimal systemic absorption
-
fda.gov
In clinical practice, these topical formulations are primarily indicated for the treatment of bacterial vaginosis in non-pregnant and pregnant patients
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.